

22 December 2011 EMA/973338/2011 Committee for Medicinal Products for Veterinary Use (CVMP)

CVMP Monthly report of application procedures, guidelines and related documents

December 2011

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

A pre-notification checklist is being published with this report to assist marketing authorisation holders in their submissions of Type IA variations, as well as a template letter to cover all veterinary procedures.

Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

| Scientific advice requests | | | | | | | | | |
|-----------------------------|-------|------|------|------|-------|--|--|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | | | |
| Submitted | 69 | 11 | 21 | 26 | 127 | | | | |
| Advice given 65 8 18 24 115 | | | | | | | | | |

| Initial evaluation | | | | | | | | |
|--------------------|-------|------|------|------|-------|--|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | | |
| Full | 110 | 14 | 16 | 8 | 148 | | | |
| (Submitted) | | | | | | | | |
| Abridged/ | 10 | 1 | 2 | 3 | 16 | | | |
| generics | | | | | | | | |
| (Submitted) | | | | | | | | |
| Withdrawals | 12 | 0 | 1 | 0 | 13 | | | |
| Positive | 91 | 13 | 14 | 19 | 137 | | | |
| opinions | | | | | | | | |
| Negative | 1 | 0 | 0 | 0 | 1 | | | |
| opinions | | | | | | | | |

| Marketing authorisations | | | | | | | |
|--------------------------|-------|------|------|------|-------|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | |
| Granted | 88 | 12 | 9 | 22 | 131 | | |
| Withdrawals | 2 | 0 | 4 | 1 | 7 | | |
| Not renewed | 2 | 0 | 0 | 0 | 2 | | |

| Extensions | | | | | | | | | |
|-------------|-------|------|------|------|-------|--|--|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | | | |
| Submitted | 60 | 12 | 3 | 7 | 82 | | | | |
| Withdrawals | 2 | 1 | 1 | 0 | 4 | | | | |
| Positive | 40 | 7 | 8 | 4 | 59 | | | | |
| opinions | | | | | | | | | |
| Negative | 0 | 0 | 0 | 0 | 0 | | | | |
| opinions | | | | | | | | | |



| Variations – applications submitted | | | | | | | |
|-------------------------------------|-------|------|------|------|-------|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | |
| Type IA | 339 | 32 | 76 | 125 | 763 | | |
| Type IB | 339 | 41 | 63 | 87 | 703 | | |
| Type II | 210 | 40 | 26 | 45 | 321 | | |
| Transfers | 11 | 3 | 8 | 3 | 25 | | |

| Renewals | | | | | | | | |
|-----------|-------|------|------|------|-------|--|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | | |
| Submitted | 50 | 18 | 7 | 14 | 89 | | | |
| Positive | 48 | 17 | 8 | 12 | 85 | | | |
| opinions | | | | | | | | |
| Negative | 0 | 0 | 0 | 0 | 0 | | | |
| opinions | | | | | | | | |

| Arbitrations and Community referrals | | | | | | | |
|--------------------------------------|-------|------|------|------|-------|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | |
| Referrals submitted | 38 | 9 | 12 | 12 | 71 | | |
| Opinions | 20 | 15 | 11 | 10 | 56 | | |
| reached ¹ | | (5) | (1) | | (6) | | |

¹ Re-examination of opinions in brackets

| Substances considered as not falling within the scope of Regulation (EC) No 470/2009 | | | | | |
|--|------|-------|--|--|--|
| | 2011 | Total | | | |
| Submitted | 7 | 7 | | | |
| Agreed | 9 | 9 | | | |
| Scientific advice recommended | 0 | 0 | | | |

| MUMS/ Limited market classification | | | | | | |
|-------------------------------------|------|-------|--|--|--|--|
| | 2011 | Total | | | | |
| Positive with financial incentives | 8 | 8 | | | | |
| Positive without financial | 12 | 12 | | | | |
| incentives | | | | | | |
| Negative | 1 | 1 | | | | |

| Establishment of MRLs for new substances | | | | | | | | |
|--|-------|------|------|------|-------|--|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | | |
| Submitted | 66 | 4 | 3 | 1 | 74 | | | |
| Withdrawals | 5 | 0 | 0 | 0 | 5 | | | |
| Positive | 54 | 2 | 2 | 4 | 62 | | | |
| opinions ² | | | | | | | | |
| Negative | 7 | 0 | 0 | 0 | 7 | | | |
| opinions ³ | | | | | | | | |

| Extensions / modifications/extrapolations of MRLs | | | | | | | | |
|---|-------|------|------|------|-------|--|--|--|
| | 95-08 | 2009 | 2010 | 2011 | Total | | | |
| Submitted | 98 | 2 | 10 | 13 | 123 | | | |
| Withdrawals | 4 | 0 | 0 | 2 | 6 | | | |
| Positive opinions ² | 113 | 3 | 3 | 12 | 131 | | | |
| Negative opinions | 6 | 0 | 0 | 0 | 6 | | | |

² Including opinions recommending the extension of the expiry date for provisional MRLS or definitive MRLs for substances with previously provisional maximum residue limits

MRLs for substances with previously provisional maximum residue limits

³ Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

CVMP opinions in 2011 on medicinal products for veterinary use

Positive opinions

| Pre | oduct | • | Marketing | Th | erapeutic area | EM | IA/CVMP | Eu | ropean |
|-----|-------------------------|----------|---------------------------|----|-------------------------|-----|--------------------------|----|--------------------------|
| | Invented | | authorisation | • | Target species | • | Validation | Co | mmission |
| • | name | | holder | • | Summary of | • | Opinion | • | Opinion |
| | INN | | | | indication | • | Active time | | received |
| | 21414 | | | | | • | Clock stop | • | Date of decision |
| | | | | | | | | • | Notification |
| | | | | | | | | • | Official Journal |
| • | CaniLeish | • | Virbac S.A. | • | Dogs | • | 17/03/2010 | • | 13/01/2011 |
| | | | | • | Vaccine against | • | 12/01/2011 | • | 14/03/2011 |
| | | | | | Leishmania infection | • | 210 | • | 17/03/2011 |
| | | | | | | • | 91 | • | OJ C 184/15 |
| • | ZULVAC 1 + 8 | • | Pfizer Limited | • | Sheep | • | 18/03/2010 | • | 13/01/2011 |
| | Ovis | | | • | Vaccine for | • | 12/01/2011 | • | 14/03/2011 |
| | | | | | prevention of | • | 180 | • | 17/03/2011 |
| | | | | | viraemia caused by | • | 119 | • | OJ C 184/15 |
| | | | | | Bluetongue Virus | | | | |
| | | | | | serotypes 1 and 8 | | | | |
| • | BLUEVAC BTV8 | • | CZ Veterinaria | • | Cattle, sheep | • | 17/01/2009 | • | 10/02/2011 |
| | | | S.A | • | Vaccine for active | • | 09/02/2011 | • | 14/04/2011 |
| | | | | | immunisation against | • | 210 | • | 18/04/2011 |
| | | | | | bluetongue disease | • | 543 | • | OJ C 184/15 |
| • | Procox | • | Bayer Animal | • | Dogs | • | 16/02/2010 | • | 11/02/2011 |
| • | Emodepside | | Health GmbH | • | Treatment of dogs | • | 09/02/2011 | • | 20/04/2011 |
| | and toltrazuril | | | | when mixed parasitic | • | 210 | • | 28/04/2011 |
| | | | | | infections, caused by | • | 148 | • | OJ C 184/15 |
| | | | | | certain specific | | | | |
| | | | | | roundworms and | | | | |
| | | | | | coccidia are | | | | |
| | | | | | suspected or | | | | |
| |) / - · - C¹ | | Danier A. J. | | demonstrated | | 10/05/2022 | | 11/02/2011 |
| • | Veraflox | • | Bayer Animal | • | Dogs, cats | • | 19/05/2009 | • | 11/02/2011 |
| • | Pradofloxacin | | Health GmbH | • | Treatment for dogs | • | 14/07/2010 | • | 12/04/2011 |
| | | | | | and cats with | • | 205 | • | 14/04/2011 |
| | | | | | particular infections | • | 217 | • | OJ C 184/15 |
| | | | | | caused by certain | • | 09/02/2011 | | |
| | | | | | specific and | (re | ·- | | |
| | | | | | susceptible | COI | nsideration) | | |
| | Zuprovo | _ | Intervet | _ | pathogens Pigs, cattle | _ | 16/02/2010 | _ | 10/03/2011 |
| | Zuprevo Tildipirosin | • | Intervet International BV | • | Treatment of | • | 16/02/2010 08/03/2011 | • | 10/03/2011 06/05/2011 |
| | i iluipii USIII | | THE HAUDIN DV | • | bacterial infections in | • | 210 | • | 06/05/2011 |
| | | | | | the respiratory tract | | 177 | • | OJ C 250/16 |
| | | | | | in pigs and cattle | • | 1// | • | 01 C 230/10 |
| | CERTIFECT | • | MERIAL SAS | • | Dogs | • | 16/03/2010 | • | 10/03/2011 |
| | | • | HEIMAL SAS | | Treatment and | | | | 06/05/2011 |
| | Fipronil, (S)- | <u> </u> | | • | meannem and | • | 09/03/2011 | • | 00/03/2011 |

| Pro | oduct | • | Marketing | Th | erapeutic area | EM | IA/CVMP | Eu | ropean |
|-----|---|---|-----------------------------------|----|--|----|--|----|---|
| | Invented | | authorisation | • | Target species | • | Validation | | mmission |
| • | name INN | | holder | • | Summary of indication | • | Opinion Active time Clock stop | • | Opinion received Date of decision Notification Official Journal |
| | methoprene, amitraz | | | | prevention of infestations with ticks, alone or in association with fleas and/or chewing lice | • | 210 148 | • | 06/05/2011 OJ C 250/16 |
| • | MS-H Vaccine Mycoplasma synoviae strain MS-H | • | Pharmsure Ltd | • | Chickens Vaccine to reduce air sac lesions and reduce the number of eggs with abnormal shell formation caused by Mycoplasma synoviae | • | 15/12/2009 07/04/2011 206 271 | • | 08/04/2011 14/06/2011 14/06/2011 OJ C 250/16 |
| • | Recuvyra Fentanyl | • | Nexcyon Pharmaceuticals Ltd | • | Dogs Control of post- operative pain associated with major orthopaedic and soft tissue surgery | • | 16/12/2009 04/05/2011 210 294 | • | 05/05/2011 |
| • | Emdocam Meloxicam | • | Emdoka bvba | • | Cattle, pigs, horses For treatment in respiratory infections, diarrhoea and mastitis in cattle. For treatment in non-infectious locomotor disorders and in puerperal septicaemia and toxaemia in pigs. In horses for treatment in musculo-skeletal disorders as well for the relief of pain in equine colic. | • | 18/05/2010 09/06/2011 175 211 | • | 09/06/2011 18/08/2011 22/08/2011 OJ C 316/15 |
| • | Proteq West Nile West Nile recombinant | • | MERIAL | • | Horses Vaccine for the active immunisation of horses against | • | 18/05/2010 09/06/2011 196 190 | • | 09/06/2011 05/08/2011 10/08/2011 OJ C 316/15 |

| Product | Marketing | | Therapeutic area | | EM | IA/CVMP | Eu | ropean |
|--|-------------------------------|----------------------------|------------------|--|----|--|----|---|
| • Invented | | authorisation | • | Target species | • | Validation | Co | mmission |
| name INN | | holder | • | Summary of indication | • | Opinion Active time Clock stop | • | Opinion received Date of decision Notification Official Journal |
| canarypox virus (vCP2017 virus) | | | | West Nile disease | | | | |
| Zulvac 1 Bovis Inactivated Bluetongue virus, serotype 1, strain BTV-1 | • | Pfizer Limited | • | Cattle Active immunisation of cattle for the prevention of viraemia caused by Bluetongue Virus, serotype 1 | • | 12/08/2010 09/06/2011 180 120 | • | 06/07/2011 05/08/2011 10/08/2011 OJ C 316/15 |
| Zulvac 1 Ovis Inactivated Bluetongue Virus, serotype 1, strain BTV-1 | • | Pfizer Limited | • | Sheep Active immunisation of sheep for the prevention of viraemia caused by Bluetongue Virus, serotype 1 | • | 15/07/2010 09/06/2011 179 148 | • | 06/07/2011 05/08/2011 10/08/2011 OJ C 316/15 |
| Nobivac Myxo- RHD Live myxoma vectored RHD virus strain 009 | | Intervet International BV, | • | Rabbits Active immunisation of rabbits to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease | • | 16/02/2010 14/07/2011 210 302 | • | 15/07/2011 07/09/2011 |
| Recocam Meloxicam | • | CF Pharma | • | Cattle, pigs, horses For treatment in respiratory infections, diarrhoea and mastitis in cattle. For treatment in non-infectious locomotor disorders and in puerperal septicaemia and toxaemia in pigs. In horses for treatment in musculo-skeletal disorders as well for the relief of pain in | • | 16/03/2010 14/07/2011 210 274 | • | 14/07/2011 13/09/2011 |

| Product | | • | Marketing | Therapeutic area | | EMA/CVMP | | European | |
|---------|-------------------------|---|-----------------|------------------|-------------------------------------|----------|--------------------------|----------|----------------------------|
| • | Invented | | authorisation | • | Target species | • | Validation | Со | mmission |
| | name | | holder | • | Summary of indication | • | Opinion Active time | • | Opinion |
| • | INN | | | | illuication | • | Clock stop | • | received Date of decision |
| | | | | | | | Clock Stop | | Notification |
| | | | | | | | | • | Official Journal |
| | | | | | equine colic. | | | | |
| • | TruScient | • | Pfizer Limited | • | Dogs | • | 15/06/2010 | • | 14/10/2011 |
| • | Dibotermin- | | | • | For the treatment of | • | 13/10/2011 | • | 14/12/2011 |
| | alfa | | | | diaphyseal fractures | • | 205 | | |
| | | | | | as an adjunct to | • | 279 | | |
| | | | | | standard surgical | | | | |
| | | | | | care using open | | | | |
| | _ | | | | fracture reduction | | 40/40/22:5 | | 4.0.44.0.40.0.11 |
| • | Panacur | • | Intervet | • | Pigs | • | 12/10/2010 | • | 13/10/2011 |
| | AquaSol | | International | • | For the treatment | • | 13/10/2011 | | |
| • | Fenbendazole | | B.V. | | and control of | • | 202 163 | | |
| | | | | | gastro-intestinal nematodes in pigs | • | 163 | | |
| | | | | | infected with Ascaris | | | | |
| | | | | | suum and | | | | |
| | | | | | Oesophagostomum | | | | |
| | | | | | spp. | | | | |
| • | Inflacam | • | Chanelle | • | Dogs, horses, cattle, | • | 15/06/2011 | • | 13/10/2011 |
| • | Meloxicam | | Pharmaceuticals | | pigs | • | 13/10/2011 | | |
| | | | Manufacturing | • | For the alleviation of | • | 120 | | |
| | | | Limited | | inflammation and | • | 0 | | |
| | | | | | pain in both acute | | | | |
| | | | | | and chronic musculo- | | | | |
| - | _ | | | | skeletal disorders. | | | | |
| • | Activyl Tick | • | Intervet | • | Dogs | • | 07/12/2010 | • | 11/11/2011 |
| | Plus | | International | • | Treatment of flea | • | 10/11/2011 | | |
| • | Indoxacarb, | | B.V. | | and tick infestations | • | 210 | | |
| _ | permethrin RevitaCAM | _ | Abbott | _ | Dogs | • | 128 | _ | 08/12/2011 |
| • | 5mg/ml | • | Laboratories | • | Dogs For the alleviation of | • | 05/01/2011 08/12/2011 | • | 08/12/2011 |
| | Jilig/IIII | | Limited | | inflammation and | • | 210 | | |
| | | | Littliccu | | pain in acute and | | 128 | | |
| | | | | | chronic musculo- | | | | |
| | | | | | skeletal disorders | | | | |

CVMP opinions in 2011 on establishment of MRLs

Positive opinions

| • | Substance INN | • | Target species | EN | 1A/CVMP | | uropean ommission |
|---|--|---|--------------------------------------|----|--|---|--|
| • | INN | | | • | Validation Opinion Active time Clock stop | • | Opinion received Date of regulation Official Journal |
| | Methylpredni – solone fter provisional RLs) | • | Bovine | • | n/a 12/01/2011 90 0 | • | 27/01/2011 |
| • | Octenidine dihydrochloride | • | All mammalian food producing species | • | 11/08/2009 08/02/2011 210 246 | • | 21/02/2011 |
| - | Monepantel fter provisional RLs) | • | Caprine | • | n/a 09/03/2011 90 0 | • | 25/03/2011 |
| • | Azamethiphos | • | Fin fish | • | 21/02/2011 07/04/2011 45 0 | • | 08/04/2011 |
| • | Pegylated bovine granulocyte colony stimulating factor | • | Bovine | • | 16/03/2010 05/05/2011 210 205 | • | 18/05/2011 |
| • | Lasalocid | • | Bovine | • | 10/08/2010 05/05/2011 210 58 | • | 18/05/2011 |
| • | Ivermectin | • | All mammalian food producing species | • | n/a 09/06/2011 176 0 | • | 20/06/2011 |
| • | Phenoxymethyl- penicillin | • | Poultry eggs | • | 12/10/2010 14/07/2011 210 65 | • | 22/07/2011 |
| - | Tildipirosin fter provisional RLs) | • | Bovine, porcine and caprine | • | n/a 15/09/2011 90 n/a | • | 29/09/2011 |

| Altrenoge | st • | Porcine, equidae | n/a13/10/2011129n/a | • 18/10/2011 |
|-------------|----------|---|--|--------------|
| Neomycin | • | All food producing species | 14/09/2010 10/11/2011 210 212 | • 16/11/2011 |
| • Closantel | • | Bovine and ovine milk | n/a10/11/2011830 | • 16/11/2011 |
| Nitroxinil | • | Bovine and ovine milk | n/a10/11/2011720 | • 16/11/2011 |
| Triclabence | dazole • | All ruminants | n/a10/11/2011830 | • 16/11/2011 |
| Fenbenda | zole • | Chicken and all food producing species except fish. | 13/07/2011 08/12/2011 148 0 | • 14/12/2011 |
| • Clorsulon | • | Bovine milk | n/a08/12/20111110 | • 14/12/2011 |

Arbitrations and Community referrals in 2011

| Type of referral | Date of clock start | Product name |
|------------------------|----------------------------------|---|
| | CVMP opinion | • INN |
| Referral under Art. 34 | • 11/11/2009 | Fortekor vet and associated names |
| of Directive | • 10/11/2011 | Danasaa siil kuudua ahlasiida |
| 2001/82/EC | | Benazepril hydrochloride |
| Referral under Art. 34 | • 14/04/2010 | Synulox Lactating Cow and associated names |
| of Directive | • 07/06/2011 | Amovicillia, elevadorio seid predeiselene |
| 2001/82/EC | | Amoxicillin, clavulanic acid, prednisolone |
| Referral under Art. | • 14/07/2010 | Combimox Lactating Cow |
| 33(4) of Directive | • 07/04/2011 | Americallia alcumbario said anadairelens |
| 2001/82/EC | | Amoxicillin, clavulanic acid, prednisolone |
| Referral under Art. | • 14/07/2010 | Nisamox Lactating Cow |
| 33(4) of Directive | • 07/04/2011 | A manufailling planning in a sid on a duisalana |
| 2001/82/EC | | Amoxicillin, clavulanic acid, prednisolone |
| Referral under Art. | • 14/07/2010 | Combisyn Lactating Cow |
| 33(4) of Directive | • 07/04/2011 | Amazziailia alauulania asid muuduisalana |
| 2001/82/EC | | Amoxicillin, clavulanic acid, prednisolone |

| Type of referral | Date of clock startCVMP opinion | Product nameINN |
|--|--|---|
| Referral under Art. 34 | • 14/07/2010 | Doxycycline 50% WSP and associated names |
| of Directive | • 04/05/2011 | Doxycycline hyclate |
| 2001/82/EC Referral under Art. 34 | • 14/07/2010 | Doxyfar 50% WSP and associated names |
| of Directive 2001/82/EC | • 04/05/2011 | Doxycycline hyclate |
| Referral under Art. 34 of Directive | • 09/11/2010 | Baytril 10% oral solution and associated names |
| 2001/82/EC | | Enrofloxacin |
| Referral under Art. | • 09/02/2011 | Clavudale 50 mg tablet for cats and dogs |
| 33(4) of Directive 2001/82/EC | • 08/06/2011 | Amoxicillin and clavulanic acid |
| Referral under Art. 35 of Directive 2001/82/EC | • 09/03/2011 | Veterinary medicinal products containing active substances belonging to the class of flukicides for which no MRL has been established in milk |
| Referral under Art. 35 of Directive 2001/82/EC | • 06/04/2011 • 13/10/2011 | All veterinary medicinal products containing systemically administered (parenteral and oral) 3rd and 4th generation cephalosporins and intended for use in food producing species |
| | | Cefquinome and ceftiofur |
| Referral under Art. | • 04/05/2011 | Prontax 5 mg/ml pour-on solution for cattle |
| 33(4) of Directive 2001/82/EC | | Doramectin |
| Referral under Art. 33(4) of Directive | • 04/05/2011 | Prontax 10 mg/ml solution for injection for sheep, cattle and pigs |
| 2001/82/EC | | Doramectin |
| Referral under Art. 35 of Directive 2001/82/EC | • 04/05/2011 | All pre-mixes for medicated feedingstuffs containing 40, 100 or 200 g tilmicosin per kg pre-mix |
| | | Tilmicosin |
| Referral under Art. 78 of Directive | 04/05/201114/07/2011 | HIPRABOVIS PNEUMOS Emulsion for injection for cattle and associated names |
| 2001/82/EC | | Inactivated Mannheimia haemolytica and Histophilus somni |
| Referral under Art. 34 of Directive 2001/82/EC | • 14/09/2011 | Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus and associated names |

| Type of referral | Date of clock startCVMP opinion | • Product name • INN |
|---|--|---|
| | | Praziquantel, pyrantel and febantel |
| Referral under Art. 35 of Directive 2001/82/EC | • 15/09/2011 | All long acting formulations for injection containing barium selenate for all food producing species barium selenate |
| | | barium seienate |
| Procedure under Art. 30(3) of Regulation (EC) No 726/2004 | • 15/09/2011 | N/aDapsone |
| Procedure under Article 33(4) of Directive 2001/82/EC | • 12/10/2011 | Nuflor 300 mg/ml solution for injection for cattle and sheep Florfenicol |
| Procedure under Article 35 of Directive 2001/82/EC | • 12/10/2011 | Hipralona Enro-S and its genericsEnrofloxacin |

Guidelines and working documents in 2011

CVMP Quality

| Reference number | Document title | Status |
|------------------------------|---|--|
| EMA/CVMP/VICH/502/1999-Rev.1 | VICH GL18(R) on residual solvents in new veterinary medicinal products, active substances and excipients | Adopted September 2011 |
| EMA/CVMP/814/00-Rev.2 | HMPC Guideline on quality of herbal medicinal products/traditional herbal medicinal products | Adopted September 2011 |
| EMA/CVMP/815/00-Rev.2 | Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products | Adopted September 2011 |
| EMA/CVMP/VICH/858875/2011 | VICH GL51 on Quality: Statistical evaluation of stability data | Adopted for consultation, December 2011 (End of consultation 12 June 2012) |

CVMP Efficacy

| Reference number | Document title | Status |
|-----------------------------------|---|------------------------------------|
| EMA/CVMP/016/00-Rev.3 | Guideline on the conduct of bioequivalence studies for veterinary medicinal products | Adopted April 2011 |
| EMA/CVMP/760764/2010 | Concept paper on the revision of | Adopted for consultation, |
| | the CVMP Guideline for the | April 2011 |
| | demonstration of efficacy for veterinary medicinal products containing antimicrobial substances | (End of consultation 31 July 2011) |
| EMA/CVMP/EWP/459868/2008 | Guideline on demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish | Adopted May 2011 |
| EMA/CVMP/EWP/325284/2011 | Questions and Answers document in relation to the CVMP Guideline on pharmaceutical fixed combination products (EMEA/CVMP/83804/05) | Adopted October 2011 |
| EMA/CVMP/EWP/82829/2009- Rev.1 | Question and Answer document in relation to the CVMP guideline on testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats. | Adopted November 2011 |

CVMP Safety

| Reference number | Document title | Status |
|----------------------------|-------------------------------------|------------------------------|
| EMEA/CVMP/VICH/463072/2009 | VCHI GL46: Metabolism study to | Adopted March 2011 |
| | determine the quantity and identify | |
| | the nature of residues | |
| EMEA/CVMP/VICH/463104/2009 | VCHI GL47: Laboratory animals | Adopted March 2011 |
| | comparative metabolism studies | |
| EMEA/CVMP/VICH/463199/2009 | VCHI GL48: Marker residue | Adopted March 2011 |
| | depletion studies to establish | |
| | product withdrawal periods | |
| EMEA/CVMP/VICH/463202/2009 | VCHI GL49: Validation of analytical | Adopted March 2011 |
| | methods used in residue depletion | |
| | studies | |
| EMA/CVMP/VICH/467/2003 | VCHI GL36: General approach to | Adopted for consultation, |
| | establish a microbiological ADI | March 2011 |
| | | (End of consultation 14 |
| | | September 2011) |
| | | |
| EMA/CVMP/90250/2010 | Draft Guideline on risk | Adopted for consultation, |
| | characterisation an assessment of | September 2011 |
| | maximum residue limits (MRLs) for | (End of consultation 30 June |

| Reference number | Document title | Status |
|------------------|----------------|--------|
| | biocides. | 2012) |

CVMP Environmental Risk Assessment

| Reference number | Document title | Status |
|------------------------------------|--|---|
| EMA/CVMP/ERA/147844/2011 | Reflection paper on the testing strategy and risk assessment for plants | Adopted December 2011 |
| EMA/CVMP/ERA/430327/2009 | Guideline on determining the fate of veterinary medicinal products in manure | Adopted March 2011 |
| EMA/CVMP/ERAWP/409328/2010 | Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products | Adopted for consultation, May 2011 (End of consultation 31 August 2011) |
| EMA/CVMP/ERA/172074/2008- Rev.3 | Questions and answers document on implementation of ERA Guideline in support of VICH guidelines (GL 6 and GL 38) | Adopted July 2011 |

CVMP Immunologicals

| Reference number | Document title | Status |
|--------------------------|---|--|
| EMA/CVMP/IWP/206555/2010 | Guideline on requirements for the production and control of immunological veterinary medicinal products | Adopted for consultation, March 2011 (End of consultation 30 September 2011) |
| EMA/CVMP/IWP/314550/2010 | Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines | Adopted November 2011 |
| EMA/CVMP/IWP/785621/2011 | Concept paper on the need of revision of the position paper on indications for veterinary vaccines | Adopted for consultation, October 2011 (End of consultation 15 January 2012) |
| EMA/CVMP/IWP/314550/2010 | Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines | Adopted November 2011 |
| EMA/CVMP/IWP/594618/2010 | Guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs) | Adopted for consultation, November 2011 (End of consultation 30 April 2012) |
| EMA/CVMP/VICH/463/2002 | VICH GL34 on Biologicals: Mycoplasma - Test for the detection | Adopted for consultation, December 2011 |

| Reference number | Document title | Status |
|---------------------------|---|--|
| | of Mycoplasma contamination | (End of consultation 12 March 2012) |
| EMA/CVMP/VICH/582610/2009 | VICH GL50 on Biologicals: Testing harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use | Adopted for consultation, December 2011 (End of consultation 12 June 2012) |
| EMA/675371/2011 | EMA report on the implementation of the possibility for waiving the target animal batch safety test for immunological veterinary medicinal products in the European Union | Endorsed December 2011 |

CVMP Pharmacovigilance

| Reference number | Document title | Status |
|--------------------------------------|--|-----------------------|
| EMA/CVMP/PhVWP/471721/2006 | Recommendation on the basic surveillance of EudraVigilance Veterinary (EVVet) data | Adopted February 2011 |
| EMA/CVMP/PhVWP/44873/2011 | Public bulletin - Veterinary pharmacovigilance for 2010 | Adopted February 2011 |
| EMA/CVMP/10418/2009-Rev.3 | CVMP combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products | Adopted June 2011 |
| EMA/CVMP/PhVWP/377827/2011 | List of species and breeds for electronic reporting of suspected adverse reactions in veterinary pharmacovigilance | Adopted June 2011 |
| EMA/CVMP/PhVWP/288284/2007- Rev.4 | Guidance notes on the use of VeDDRA terminology for reporting suspected adverse reactions in animals and humans | Adopted June 2011 |
| SOP/V/4019 | Standard operating procedure - Annual review of standard lists to be used in EudraVigilance Veterinary | Adopted June 2011 |
| SOP/V/4032 | Standard operating procedure - Safety monitoring of centrally authorised products | Adopted October 2011 |

CVMP Scientific Advisory Group on Antimicrobials

| Reference number | Document title | Status |
|----------------------------|---|--|
| EMA/CVMP/SAGAM/736964/2009 | Reflection paper on meticillin- resistant <i>Staphylococcus</i> pseudintermedius (MRSP) | Adopted January 2011 |
| EMA/CVMP/287420/2010 | CVMP Strategy on antimicrobials 2011-2015 | Adopted July 2011 |
| EMA/CVMP/SAGAM/435644/2011 | Concept paper on Use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health | Adopted for consultation, October 2011 (End of consultation 31 January 2012) |
| EMA/CVMP/SAGAM/741087/2009 | Reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal health | Adopted for consultation, October 2011 |

General

| Reference number | Document title | Status |
|----------------------|--|-----------------------|
| EMA/347137/2010 | Summary of procedures for consultation by CVMP of Scientific Advisory Groups (SAGs) and ad-hoc expert groups functioning as SAGs in relation to applications for authorisation for veterinary medicinal products | Adopted February 2011 |
| EMA/CVMP/287420/2010 | CVMP Strategy on antimicrobials 2011-2015 | Adopted July 2011 |
| EMA/CVMP/414812/2011 | Question and answer document on the CVMP guideline on the SPC for antimicrobial products | Adopted July 2011 |